Lixte Biotechnology Holdings, Inc.
NASDAQ:LIXTBiotechnology
Healthcare
$7.21 +6.61%
+$0.46 today
- Market cap
- $89.11M
- Beta
- 1.05
- P/E (TTM)
- -11.1
- EPS (TTM)
- -$0.67
52W Low $0.68High $7.78
Volume 0.61M
Average 0.12M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$5.11M
FY 2025 · Annual
Net Income
-$6.01M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 1.74M | 1.35M | 898.1K | 726.23K | 254.92K |
| Selling, General & Admin | 4.98M | 4.96M | 4.19M | 2.85M | 4.85M |
| Operating Expenses | 6.72M | 6.31M | 5.09M | 3.57M | 5.11M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| EBITDA | (6.72M) | (6.3M) | (5.07M) | (3.57M) | (6M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (6.72M) | (6.31M) | (5.09M) | (3.57M) | (5.11M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 626 | 11.2K | 17.49K | 7.05K | 7.39K |
| Interest Expense | 7.41K | 8.88K | 16.23K | 16.82K | 9.16K |
| Other Income / Expenses | (7.95K) | (1.05K) | 3.21K | (13.18K) | (901.9K) |
| Income Before Tax | (6.73M) | (6.31M) | (5.09M) | (3.59M) | (6.01M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (6.73M) | (6.31M) | (5.09M) | (3.59M) | (6.01M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (5.00) | (4.00) | (2.66) | (1.59) | (1.26) |
| EPS (Diluted) | (5.00) | (4.00) | (2.66) | (1.59) | (1.26) |
| 1.35M | 1.58M | 1.91M | 2.25M | 48.41M | |
| 1.35M | 1.58M | 1.92M | 2.25M | 48.41M |
LIXT Earnings Waterfall · TTM
NASDAQ:LIXT · Revenue to Net Income
Key Ratios
EPS$-1.13
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-6.9
P/S Ratio0.0
Analysis
$0 of revenue converted into -$7.3M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.13, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 3 | Initial statement of beneficial ownership | Jul 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jul 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jul 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jul 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jul 2, 2026 |
How much revenue does LIXT generate?
Lixte Biotechnology Holdings, Inc. (LIXT) reported $0.00 of revenue in fiscal 2025.
Is LIXT profitable?
Lixte Biotechnology Holdings, Inc. (LIXT) reported -$6.01M of net income.
Continue the stock analysis
Jump to another research area for this company.